Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of VX-121 triple-combination therapy in adults with cystic fibrosis
NL-OMON48070Phase 2Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vanzacaftor, tezacaftor, deutivacaftor and ivacaftor in cystic fibrosis (CF) (6 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety and tolerability and Absolute change in ppFEV1 through Day 29. Started Aug 2019; status: active, not recruiting.
02
Drugs
vanzacaftortezacaftordeutivacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON48070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48070.